V. V. Prokofiev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
V. V. Prokofiev has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Ekaterina I. Ryabova
Gamaleya National Research Center of Epidemiology and Microbiology, Moscow, Russia
7 shared publications - Ilias B. Esmagambetov
N.F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation
7 shared publications - Artem A. Derkaev
N.F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation
4 shared publications - Dmitry Shcheblyakov
N. F. Gamaleya Federal Research Center for Epidemiology & Microbiology, Ministry of Health, Moscow 123098, Russia
4 shared publications - Alexander V. Gromov
The Gamaleya Research Center of Epidemiology and Microbiology;Centre for Strategic Planning of FMBA of Russia
2 shared publications - D. S. Polyansky
MIREA – Russian Technological University (M.V. Lomonosov Institute of Fine Chemical Technologies)
2 shared publications
Latest Publications
- Open Access
- 6 May 2026
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 21 (2) , 188-211
Development and scaling of a chromatographic purification technology for single-domain antibodies fused to the Fc fragment of human IgG1
Objectives. The work set out to develop a chromatographic purification technology for drugs based on modified single-domain antibodies specific to the SARS-CoV-2 virus, as well as to select the optimal parameters for the purification process and scale up this technology for production. Methods. The study was conducted on a culture of Chinese hamster ovary (CHO) cells GAMP2C5 clone 78, CHO B5 clone 4, and CHO B10 clone 4, which were used to produce modified single-domain antibodies GAMP2C5, GAMB5, and GAMB10, respectively. Chromatographic purification was performed using AKTA pure 25 and AKTA Pilot 600s chromatographs. Quality control of the obtained drugs was carried out using high-performance liquid chromatography, capillary gel electrophoresis, dynamic light scattering, enzymelinked immunosorbent assay, and polymerase chain reaction. Results. Multimodal chromatography using CA ++ Pure-HA ( TOSOH , Japan) resin based on type 1 ceramic hydroxyapatite can be effectively used for the removal of aggregated antibody forms. The drugs obtained after chromatography using CA ++ Pure-HA resin based on type 1 ceramic hydroxyapatite have a purity of more than 97%. The developed purification technology was scaled up to purify 200 L of culture fluid after cultivation in an STR 200 bioreactor. Conclusions. The described technology developed for purifying modified mono-domain antibodies using the CA ++ Pure-HA multimodal resin based on type 1 ceramic hydroxyapatite allows for the effective removal of low-molecular-weight impurities and aggregated forms of the antibody. The antibodies obtained using the developed technology are characterized by a high degree of purity and the absence of various impurities (residual protein of the producer strain, residual protein A, and residual DNA of the producer strain), as well as offering a hydrodynamic molecular radius corresponding to the theoretical value of monomeric forms of antibodies.
- 6 May 2026
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 21 (2) , 188-211
Open AccessDevelopment and scaling of a chromatographic purification technology for single-domain antibodies fused to the Fc fragment of human IgG1
Objectives. The work set out to develop a chromatographic purification technology for drugs based on modified single-domain antibodies specific to the SARS-CoV-2 virus, as well as to select the optimal parameters for the purification process and scale up this technology for production. Methods. The study was conducted on a culture of Chinese hamster ovary (CHO) cells GAMP2C5 clone 78, CHO B5 clone 4, and CHO B10 clone 4, which were used to produce modified single-domain antibodies GAMP2C5, GAMB5, and GAMB10, respectively. Chromatographic purification was performed using AKTA pure 25 and AKTA Pilot 600s chromatographs. Quality control of the obtained drugs was carried out using high-performance liquid chromatography, capillary gel electrophoresis, dynamic light scattering, enzymelinked immunosorbent assay, and polymerase chain reaction. Results. Multimodal chromatography using CA ++ Pure-HA ( TOSOH , Japan) resin based on type 1 ceramic hydroxyapatite can be effectively used for the removal of aggregated antibody forms. The drugs obtained after chromatography using CA ++ Pure-HA resin based on type 1 ceramic hydroxyapatite have a purity of more than 97%. The developed purification technology was scaled up to purify 200 L of culture fluid after cultivation in an STR 200 bioreactor. Conclusions. The described technology developed for purifying modified mono-domain antibodies using the CA ++ Pure-HA multimodal resin based on type 1 ceramic hydroxyapatite allows for the effective removal of low-molecular-weight impurities and aggregated forms of the antibody. The antibodies obtained using the developed technology are characterized by a high degree of purity and the absence of various impurities (residual protein of the producer strain, residual protein A, and residual DNA of the producer strain), as well as offering a hydrodynamic molecular radius corresponding to the theoretical value of monomeric forms of antibodies.
- Open Access
- 10 February 2025
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 25 (1) , 58-70
A modified single-domain antibody candidate for the treatment of botulism caused by botulinum toxin type A
INTRODUCTION. Currently, the primary treatment method for botulism is the use of botulinum antitoxin, which causes a number of side effects, including allergic reactions. The development of medicinal products based on monoclonal antibodies (mAbs), in particular, single-domain mAbs fused to the human IgG1 Fc fragment, holds promise for the treatment of botulinum toxin poisoning.AIM. This study aimed to optimise the technology for laboratory-scale production of a single-domain mAb fused to the human IgG1 Fc fragment (B11-Fc) for botulism treatment and post-exposure prophylaxis and to conduct a preclinical efficacy study of this mAb.MATERIALS AND METHODS. The study used CHO cells. B7, a stable clone producing the B11-Fc single-domain mAb, was cultured in Erlenmeyer flasks using commercially available media and feeds. The B11-Fc mAb was purified using multistep chromatography (including affinity, anion exchange, and multimodal chromatography steps), virus elimination, and tangential flow filtration. The purity of the B11-Fc mAb was assessed by high-performance liquid chromatography (HPLC) and electrophoresis. The glycan profile was established by HPLC. Bio-layer interferometry was used to measure the mAb concentration in the culture fluid and to determine the equilibrium dissociation constants for the mAb and various Fc receptors. Botulinum toxin type A (BoNT/A) was produced by culturing the Clostridium botulinum A98 strain and purified by chromatography. In vivo experiments involved intraperitoneal and intragastric administration of BoNT/A to female BALB/c mice, with a subsequent assessment of the severity of toxic signs. The B11-Fc mAb was administered intramuscularly or intravenously (to study the pharmacokinetics). The efficacy of the B11-Fc mAb (in terms of mouse survival) was studied using various toxicity models and the prophylactic and therapeutic modes of administration.RESULTS. The study optimised culture conditions for the B11-Fc mAb producer clone and developed a mAb purification technology that ensured a high yield (0.5 g/L) and a purity of over 99%. The average particle size in the mAb preparation was 7.85 nm. The study characterised the glycan profile of the B11-Fc mAb and determined the equilibrium dissociation constants for the mAb and human Fc receptors. Poisoning with BoNT/A was modelled in mice. The intramuscular administration of the B11-Fc mAb at a dose of 0.6 mg/kg provided 100% protection from poisoning with BoNT/A that was simultaneously administered at a dose of 20 LD50. The study determined the main pharmacokinetic parameters of the B11-Fc mAb. The experiments demonstrated that prophylactic administration of the B11-Fc mAb for 21 days had a protective effect against BoNT/A administered intraperitoneally at a dose of 5 LD50, and therapeutic administration of the mAb 14 h after intragastric administration of the toxin at a dose of 12,000 intraperitoneal LD50 provided 100% protection.CONCLUSIONS. The authors optimised the technology for laboratory-scale production of the candidate modified single-domain mAb. In vivo experiments conducted using BoNT/A toxicity models demonstrated that the B11-Fc mAb is highly effective in botulism prevention and treatment. On the basis of preclinical data, phase I clinical trials have been initiated to study B11-Fc in healthy volunteers.
- 10 February 2025
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 25 (1) , 58-70
Open AccessA modified single-domain antibody candidate for the treatment of botulism caused by botulinum toxin type A
INTRODUCTION. Currently, the primary treatment method for botulism is the use of botulinum antitoxin, which causes a number of side effects, including allergic reactions. The development of medicinal products based on monoclonal antibodies (mAbs), in particular, single-domain mAbs fused to the human IgG1 Fc fragment, holds promise for the treatment of botulinum toxin poisoning.AIM. This study aimed to optimise the technology for laboratory-scale production of a single-domain mAb fused to the human IgG1 Fc fragment (B11-Fc) for botulism treatment and post-exposure prophylaxis and to conduct a preclinical efficacy study of this mAb.MATERIALS AND METHODS. The study used CHO cells. B7, a stable clone producing the B11-Fc single-domain mAb, was cultured in Erlenmeyer flasks using commercially available media and feeds. The B11-Fc mAb was purified using multistep chromatography (including affinity, anion exchange, and multimodal chromatography steps), virus elimination, and tangential flow filtration. The purity of the B11-Fc mAb was assessed by high-performance liquid chromatography (HPLC) and electrophoresis. The glycan profile was established by HPLC. Bio-layer interferometry was used to measure the mAb concentration in the culture fluid and to determine the equilibrium dissociation constants for the mAb and various Fc receptors. Botulinum toxin type A (BoNT/A) was produced by culturing the Clostridium botulinum A98 strain and purified by chromatography. In vivo experiments involved intraperitoneal and intragastric administration of BoNT/A to female BALB/c mice, with a subsequent assessment of the severity of toxic signs. The B11-Fc mAb was administered intramuscularly or intravenously (to study the pharmacokinetics). The efficacy of the B11-Fc mAb (in terms of mouse survival) was studied using various toxicity models and the prophylactic and therapeutic modes of administration.RESULTS. The study optimised culture conditions for the B11-Fc mAb producer clone and developed a mAb purification technology that ensured a high yield (0.5 g/L) and a purity of over 99%. The average particle size in the mAb preparation was 7.85 nm. The study characterised the glycan profile of the B11-Fc mAb and determined the equilibrium dissociation constants for the mAb and human Fc receptors. Poisoning with BoNT/A was modelled in mice. The intramuscular administration of the B11-Fc mAb at a dose of 0.6 mg/kg provided 100% protection from poisoning with BoNT/A that was simultaneously administered at a dose of 20 LD50. The study determined the main pharmacokinetic parameters of the B11-Fc mAb. The experiments demonstrated that prophylactic administration of the B11-Fc mAb for 21 days had a protective effect against BoNT/A administered intraperitoneally at a dose of 5 LD50, and therapeutic administration of the mAb 14 h after intragastric administration of the toxin at a dose of 12,000 intraperitoneal LD50 provided 100% protection.CONCLUSIONS. The authors optimised the technology for laboratory-scale production of the candidate modified single-domain mAb. In vivo experiments conducted using BoNT/A toxicity models demonstrated that the B11-Fc mAb is highly effective in botulism prevention and treatment. On the basis of preclinical data, phase I clinical trials have been initiated to study B11-Fc in healthy volunteers.
- 29 June 2023
- Published by Ob'edinennaya Redakcya OOO in Molecular Genetics Microbiology and Virology (Russian version)
- Vol. 41 (2)
Recombinant RBD of SARS-CoV-2 spike protein: production in Escherichia coli cells, binding to antibodies and antiviral activity
ЦЕЛЬ РАБОТЫ Получение синтезом в клетках Escherichia coli рекомбинантного белка, включающего RBM Spike-белка SARS-CoV-2, не уступающего по своей противовирусной активности RBD, полученному в эукариотическом продуценте (eRBD). МАТЕРИАЛ И МЕТОДЫ Белки 6His-RBDshort (24,4 кД) и 6His-RBDlong (33,7 кД) были экспрессированы в штамме Escherichia coli BL21 (DE3). Хроматографическую очистку белков проводили на сорбентах WorkBeads 40 Ni-NTA и WorkBeads 40S с последующим многоступенчатым рефолдингом. Иммуноферментный анализ проводили с использованием гуманизированных однодоменных моноклональных антител GamP2C5 и GamXRH19, специфичных в отношении RBD Spike-белка SARS-CoV-2. Противовирусная активность в отношении вируса SARS-CoV-2 была исследована на клетках линии Vero E6. РЕЗУЛЬТАТЫ Синтезом в клетках Escherichia coli получен рекомбинантный белок 6His-RBDshort, включающий RBM (рецептор-связывающий мотив) Spike-белка вируса SARS-CoV-2 (330—527 а.о.). Проведена двухстадийная хроматографическая очистка рекомбинантного белка 6His-RBDshort с последующим рефолдингом. Иммуноферментный анализ продемонстрировал эффективное взаимодействие рекомбинантного белка 6His-RBDshort с вируснейтрализующими антителами, сравнимое с эукариотическим белком eRBD. Исследование противовирусной активности показало ингибирование размножения вируса SARS-CoV-2 после обработки клеток Vero E6 белками 6His-RBDshort (45,1%) и eRBD (42,8%). Полученный в этой же работе рекомбинантный белок 6His-RBDlong, включающий более длинный участок RBD, не взаимодействовал с вируснейтрализующими антителами и не ингибировал репликацию вируса SARS-CoV-2. ЗАКЛЮЧЕНИЕ После проведения дополнительных исследований разработанный рекомбинантный белок 6His-RBDshort может быть рассмотрен в качестве перспективного препарата для использования в терапевтических целях в качестве блокатора рецептора ACE2.
- 29 June 2023
- Published by Ob'edinennaya Redakcya OOO in Molecular Genetics Microbiology and Virology (Russian version)
- Vol. 41 (2)
Recombinant RBD of SARS-CoV-2 spike protein: production in Escherichia coli cells, binding to antibodies and antiviral activity
ЦЕЛЬ РАБОТЫ Получение синтезом в клетках Escherichia coli рекомбинантного белка, включающего RBM Spike-белка SARS-CoV-2, не уступающего по своей противовирусной активности RBD, полученному в эукариотическом продуценте (eRBD). МАТЕРИАЛ И МЕТОДЫ Белки 6His-RBDshort (24,4 кД) и 6His-RBDlong (33,7 кД) были экспрессированы в штамме Escherichia coli BL21 (DE3). Хроматографическую очистку белков проводили на сорбентах WorkBeads 40 Ni-NTA и WorkBeads 40S с последующим многоступенчатым рефолдингом. Иммуноферментный анализ проводили с использованием гуманизированных однодоменных моноклональных антител GamP2C5 и GamXRH19, специфичных в отношении RBD Spike-белка SARS-CoV-2. Противовирусная активность в отношении вируса SARS-CoV-2 была исследована на клетках линии Vero E6. РЕЗУЛЬТАТЫ Синтезом в клетках Escherichia coli получен рекомбинантный белок 6His-RBDshort, включающий RBM (рецептор-связывающий мотив) Spike-белка вируса SARS-CoV-2 (330—527 а.о.). Проведена двухстадийная хроматографическая очистка рекомбинантного белка 6His-RBDshort с последующим рефолдингом. Иммуноферментный анализ продемонстрировал эффективное взаимодействие рекомбинантного белка 6His-RBDshort с вируснейтрализующими антителами, сравнимое с эукариотическим белком eRBD. Исследование противовирусной активности показало ингибирование размножения вируса SARS-CoV-2 после обработки клеток Vero E6 белками 6His-RBDshort (45,1%) и eRBD (42,8%). Полученный в этой же работе рекомбинантный белок 6His-RBDlong, включающий более длинный участок RBD, не взаимодействовал с вируснейтрализующими антителами и не ингибировал репликацию вируса SARS-CoV-2. ЗАКЛЮЧЕНИЕ После проведения дополнительных исследований разработанный рекомбинантный белок 6His-RBDshort может быть рассмотрен в качестве перспективного препарата для использования в терапевтических целях в качестве блокатора рецептора ACE2.
- 1 June 2023
- Published by Allerton Press in Molecular Genetics, Microbiology and Virology
- Vol. 38 (2) , 86-94
Recombinant RBD of the SARS-CoV-2 Spike Protein: Production in Escherichia coli Cells, Binding to Antibodies, and Antiviral Activity
The aim of the study is to synthesize a recombinant protein in Escherichia coli cells that carries the receptor-binding domain (RBD) of Spike prot
- 1 June 2023
- Published by Allerton Press in Molecular Genetics, Microbiology and Virology
- Vol. 38 (2) , 86-94
Recombinant RBD of the SARS-CoV-2 Spike Protein: Production in Escherichia coli Cells, Binding to Antibodies, and Antiviral Activity
The aim of the study is to synthesize a recombinant protein in Escherichia coli cells that carries the receptor-binding domain (RBD) of Spike prot
- Open Access
- 20 March 2023
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 18 (1) , 48–64
Method for obtaining recombinant antibodies produced by a cell line transduced with recombinant adenoviruses
Objectives. To develop a technology for obtaining recombinant antibodies in a suspension culture of human HEK293 cells using transduction with recombinant adenovirus serotype 5 (rAd5) carrying genes expressing heavy and light chains of antibodies on the example of two broadspectrum anti-influenza antibodies 27F3 and CR9114.Methods. Ad5-27F3-H, Ad5-CR9114-H, and Ad5-27F3-L recombinant adenoviruses carrying the 27F3 antibody heavy chain gene, CR9114 antibody heavy chain gene, and 27F3 light chain gene, respectively, were generated using the AdEasy™ Adenoviral vector system. To accumulate preparative amounts of recombinant r27F3 and rCR9114 antibodies, the HEK293 suspension cell line was transduced with recombinant adenoviruses carrying genes for heavy and light chains of antibodies. The cells were cultured in a wave-type bioreactor. Chromatography was used to purify recombinant antibodies from the culture medium. After analyzing the molecular weights of purified antibodies using protein electrophoresis, their ability to interact with influenza A and B viruses was analyzed using the Western blot technique, while their ability to neutralize influenza A and B viruses was evaluated using the virus neutralization assay.Results. A method for the accumulation and purification of recombinant r27F3 and CR9114 antibodies from the culture medium of a suspension culture of human cells following transduction with its recombinant adenoviruses carrying the genes for heavy and light chains of these antibodies was developed. The ability of the r27F3 antibody to interact with and neutralize influenza A viruses of group 1 (except influenza A virus subtype H2) and group 2 was shown. The ability of the rCR9114 antibody to interact with influenza A viruses of group 1 and influenza B viruses, as well as to neutralize influenza A viruses of group 1, was demonstrated.Conclusions. A technology for obtaining recombinant antibodies in a suspension culture of HEK293 cells using transduction with recombinant adenoviruses carrying genes expressing heavy and light chains of antibodies was developed along with a confirmation of their specificity.
- 20 March 2023
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 18 (1) , 48–64
Open AccessMethod for obtaining recombinant antibodies produced by a cell line transduced with recombinant adenoviruses
Objectives. To develop a technology for obtaining recombinant antibodies in a suspension culture of human HEK293 cells using transduction with recombinant adenovirus serotype 5 (rAd5) carrying genes expressing heavy and light chains of antibodies on the example of two broadspectrum anti-influenza antibodies 27F3 and CR9114.Methods. Ad5-27F3-H, Ad5-CR9114-H, and Ad5-27F3-L recombinant adenoviruses carrying the 27F3 antibody heavy chain gene, CR9114 antibody heavy chain gene, and 27F3 light chain gene, respectively, were generated using the AdEasy™ Adenoviral vector system. To accumulate preparative amounts of recombinant r27F3 and rCR9114 antibodies, the HEK293 suspension cell line was transduced with recombinant adenoviruses carrying genes for heavy and light chains of antibodies. The cells were cultured in a wave-type bioreactor. Chromatography was used to purify recombinant antibodies from the culture medium. After analyzing the molecular weights of purified antibodies using protein electrophoresis, their ability to interact with influenza A and B viruses was analyzed using the Western blot technique, while their ability to neutralize influenza A and B viruses was evaluated using the virus neutralization assay.Results. A method for the accumulation and purification of recombinant r27F3 and CR9114 antibodies from the culture medium of a suspension culture of human cells following transduction with its recombinant adenoviruses carrying the genes for heavy and light chains of these antibodies was developed. The ability of the r27F3 antibody to interact with and neutralize influenza A viruses of group 1 (except influenza A virus subtype H2) and group 2 was shown. The ability of the rCR9114 antibody to interact with influenza A viruses of group 1 and influenza B viruses, as well as to neutralize influenza A viruses of group 1, was demonstrated.Conclusions. A technology for obtaining recombinant antibodies in a suspension culture of HEK293 cells using transduction with recombinant adenoviruses carrying genes expressing heavy and light chains of antibodies was developed along with a confirmation of their specificity.
- Open Access
- 2 January 2023
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 23 (1) , 76-89
Production and characterisation of a SARS-CoV-2 S-protein RBD homodimer with increased avidity for specific antibodies
Monitoring of the proportion of immune individuals and the effectiveness of vaccination in a population involves evaluation of several important parameters, including the level of virus-neutralising antibodies. In order to combat the COVID-19 pandemic, it is essential to develop approaches to detecting SARS-CoV-2 neutralising antibodies by safe, simple and rapid methods that do not require live viruses. To develop a test system for enzyme-linked immunosorbent assay (ELISA) that detects potential neutralising antibodies, it is necessary to obtain a highly purified recombinant receptor-binding domain (RBD) of the spike (S) protein with high avidity for specific antibodies.The aim of the study was to obtain and characterise a SARS-CoV-2 S-protein RBD homodimer and a recombinant RBD-expressing cell line, as well as to create an ELISA system for detecting potential neutralising antibodies.Materials and methods: the genetic construct was designed in silico. To generate a stable producer cell line, the authors transfected CHO-S cells, subjected them to antibiotic pressure, and selected the optimal clone. To isolate monomeric and homodimeric RBD forms, the authors purified the recombinant RBD by chromatographic methods. Further, they analysed the activity of the RBD forms by Western blotting, bio-layer interferometry, and indirect ELISA. The analysis involved mono clonal antibodies GamXRH19, GamP2C5, and h6g3, as well as serum samples from volunteers vaccinated with Gam-COVID-Vac (Sputnik V) and unvaccinated ones.Results: the authors produced the CHO-S cell line for stable expression of the recombinant SARS-CoV-2 S-protein RBD. The study demonstrated the recombinant RBD’s ability to homodimerise after fed-batch cultivation of the cell line for more than 7 days due to the presence of unpaired cysteines. The purified recombinant RBD yield from culture broth was 30–50 mg/L. Monomeric and homodimeric RBD forms were separated using gel-filtration chromatography and characterised by their ability to interact with specific monoclonal antibodies, as well as with serum samples from vaccinated volunteers. The homodimeric recombinant RBD showed increased avidity for both monoclonal and immune sera antibodies.Conclusions: the homodimeric recombinant RBD may be more preferable for the analysis of levels of antibodies to the receptor-binding domain of the SARS-CoV-2 S protein.
- 2 January 2023
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 23 (1) , 76-89
Open AccessProduction and characterisation of a SARS-CoV-2 S-protein RBD homodimer with increased avidity for specific antibodies
Monitoring of the proportion of immune individuals and the effectiveness of vaccination in a population involves evaluation of several important parameters, including the level of virus-neutralising antibodies. In order to combat the COVID-19 pandemic, it is essential to develop approaches to detecting SARS-CoV-2 neutralising antibodies by safe, simple and rapid methods that do not require live viruses. To develop a test system for enzyme-linked immunosorbent assay (ELISA) that detects potential neutralising antibodies, it is necessary to obtain a highly purified recombinant receptor-binding domain (RBD) of the spike (S) protein with high avidity for specific antibodies.The aim of the study was to obtain and characterise a SARS-CoV-2 S-protein RBD homodimer and a recombinant RBD-expressing cell line, as well as to create an ELISA system for detecting potential neutralising antibodies.Materials and methods: the genetic construct was designed in silico. To generate a stable producer cell line, the authors transfected CHO-S cells, subjected them to antibiotic pressure, and selected the optimal clone. To isolate monomeric and homodimeric RBD forms, the authors purified the recombinant RBD by chromatographic methods. Further, they analysed the activity of the RBD forms by Western blotting, bio-layer interferometry, and indirect ELISA. The analysis involved mono clonal antibodies GamXRH19, GamP2C5, and h6g3, as well as serum samples from volunteers vaccinated with Gam-COVID-Vac (Sputnik V) and unvaccinated ones.Results: the authors produced the CHO-S cell line for stable expression of the recombinant SARS-CoV-2 S-protein RBD. The study demonstrated the recombinant RBD’s ability to homodimerise after fed-batch cultivation of the cell line for more than 7 days due to the presence of unpaired cysteines. The purified recombinant RBD yield from culture broth was 30–50 mg/L. Monomeric and homodimeric RBD forms were separated using gel-filtration chromatography and characterised by their ability to interact with specific monoclonal antibodies, as well as with serum samples from vaccinated volunteers. The homodimeric recombinant RBD showed increased avidity for both monoclonal and immune sera antibodies.Conclusions: the homodimeric recombinant RBD may be more preferable for the analysis of levels of antibodies to the receptor-binding domain of the SARS-CoV-2 S protein.
- Open Access
- 16 November 2021
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 21 (4) , 266-278
Comparison of different technologies for producing recombinant adeno-associated virus on a laboratory scale
Adeno-associated virus vectors are among the most promising ones for the delivery of transgenes to various organs and tissues. Recombinant adeno-associated virus (rAAV) is able to transduce both dividing and non-dividing cells, has low immunogenicity, and is able to provide long-term expression of transgenes. Modern technologies make it possible to obtain rAAV for in vivo use, but they are not without drawbacks associated with laboriousness, scalability difficulties, and high cost, therefore, improvement of technological schemes for obtaining rAAV is an urgent issue. The aim of the study was to compare different technological approaches to rAAV production based on different conditions of the transfected HEK293 cell line cultivation on a laboratory scale. Materials and methods: HEK293 cell culture, AAV-DJ Packaging System, PlasmidSelect Xtra Starter Kit were used in the study. The technologies were compared using a model rAAV vector with a single-domain antibody transgene fused to the Fc-fragment of IgG1 specific to botulinum toxin. HEK293 cells were transfected with supercoiled plasmid DNA isolated by three-step chromatographic purification. The identity of the rAAV preparation was determined by electrophoresis, immunoblotting, and real-time polymerase chain reaction. Results: the study demonstrated the efficiency of the chromatographic method for obtaining a supercoiled form of plasmid DNA that can be used for efficient transfection of cell culture in order to produce rAAV. The study compared the following processes of rAAV production: using transient transfection and cultivation of the transfected HEK293 cell suspension in Erlenmeyer flasks, adherent culture in T-flasks, and adherent culture in a BioBLU 5p bioreactor on a matrix of Fibra-Cel disks. Conclusions: the data obtained showed the possibility of using the described approaches to purification of plasmid DNA, cell transfection, and cultivation of the transfected cells under various conditions to obtain rAAV samples that expresses the antibody gene. The BioBLU 5p reactor with Fibra-Cel discs was used for the first time to produce preparative quantities of rAAV on a laboratory scale, which increased the adherent surface area during cell culture and transfection, and, as a result, increased the yield of the target product.
- 16 November 2021
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 21 (4) , 266-278
Open AccessComparison of different technologies for producing recombinant adeno-associated virus on a laboratory scale
Adeno-associated virus vectors are among the most promising ones for the delivery of transgenes to various organs and tissues. Recombinant adeno-associated virus (rAAV) is able to transduce both dividing and non-dividing cells, has low immunogenicity, and is able to provide long-term expression of transgenes. Modern technologies make it possible to obtain rAAV for in vivo use, but they are not without drawbacks associated with laboriousness, scalability difficulties, and high cost, therefore, improvement of technological schemes for obtaining rAAV is an urgent issue. The aim of the study was to compare different technological approaches to rAAV production based on different conditions of the transfected HEK293 cell line cultivation on a laboratory scale. Materials and methods: HEK293 cell culture, AAV-DJ Packaging System, PlasmidSelect Xtra Starter Kit were used in the study. The technologies were compared using a model rAAV vector with a single-domain antibody transgene fused to the Fc-fragment of IgG1 specific to botulinum toxin. HEK293 cells were transfected with supercoiled plasmid DNA isolated by three-step chromatographic purification. The identity of the rAAV preparation was determined by electrophoresis, immunoblotting, and real-time polymerase chain reaction. Results: the study demonstrated the efficiency of the chromatographic method for obtaining a supercoiled form of plasmid DNA that can be used for efficient transfection of cell culture in order to produce rAAV. The study compared the following processes of rAAV production: using transient transfection and cultivation of the transfected HEK293 cell suspension in Erlenmeyer flasks, adherent culture in T-flasks, and adherent culture in a BioBLU 5p bioreactor on a matrix of Fibra-Cel disks. Conclusions: the data obtained showed the possibility of using the described approaches to purification of plasmid DNA, cell transfection, and cultivation of the transfected cells under various conditions to obtain rAAV samples that expresses the antibody gene. The BioBLU 5p reactor with Fibra-Cel discs was used for the first time to produce preparative quantities of rAAV on a laboratory scale, which increased the adherent surface area during cell culture and transfection, and, as a result, increased the yield of the target product.
- 1 December 2020
- Published by Pleiades Publishing Ltd in Entomological Review
- Vol. 100 (9) , 1205-1217
Seasonal Dynamics of Activity of Horseflies (Diptera, Tabanidae) in Pskov Province
We studied the seasonal dynamics of flight activity in horseflies (Diptera, Tabanidae) belonging to 30 species from 6 genera. The results show that the abundance of horseflies is largely controlled by abiotic factors, such as temperature and relative humidity. Horseflies start their flight activity at an air temperature not lower than +15°C and relative humidity not lower than 57%. There are species-specific differences in the seasonal pattern of activity. Depending on the season when activity commences, the horseflies studied can be divided into spring species (end of May), early summer species (beginning of June), and summer species (beginning of July). We attribute this variation in the timing of adult emergence to different temperature and humidity optima for larval and pupal development in different horsefly species. A routine is proposed for estimating the long-term seasonal dynamics of flight activity of horseflies with the use of weekly and monthly mean temperatures, relative air humidity, and the sum of degree-days. In a similar manner, the flight activity pattern can be projected into the future.
- 1 December 2020
- Published by Pleiades Publishing Ltd in Entomological Review
- Vol. 100 (9) , 1205-1217
Seasonal Dynamics of Activity of Horseflies (Diptera, Tabanidae) in Pskov Province
We studied the seasonal dynamics of flight activity in horseflies (Diptera, Tabanidae) belonging to 30 species from 6 genera. The results show that the abundance of horseflies is largely controlled by abiotic factors, such as temperature and relative humidity. Horseflies start their flight activity at an air temperature not lower than +15°C and relative humidity not lower than 57%. There are species-specific differences in the seasonal pattern of activity. Depending on the season when activity commences, the horseflies studied can be divided into spring species (end of May), early summer species (beginning of June), and summer species (beginning of July). We attribute this variation in the timing of adult emergence to different temperature and humidity optima for larval and pupal development in different horsefly species. A routine is proposed for estimating the long-term seasonal dynamics of flight activity of horseflies with the use of weekly and monthly mean temperatures, relative air humidity, and the sum of degree-days. In a similar manner, the flight activity pattern can be projected into the future.